![SARS-CoV-2 (COVID-19) full-length Spike Kappa (India, Dec 2020) B.1.617.1 Variant Recombinant Protein - Cat. No. 21-823 | ProSci SARS-CoV-2 (COVID-19) full-length Spike Kappa (India, Dec 2020) B.1.617.1 Variant Recombinant Protein - Cat. No. 21-823 | ProSci](https://www.prosci-inc.com/wp-content/uploads/2021/12/SARS-CoV-2-COVID-19-full-length-Spike-S1-Kappa-India-Dec-2020-B-1-617-1-Variant-Recombinant-Protein_picture_21-823.jpg)
SARS-CoV-2 (COVID-19) full-length Spike Kappa (India, Dec 2020) B.1.617.1 Variant Recombinant Protein - Cat. No. 21-823 | ProSci
![Kappa variant, which is related to more dangerous coronavirus variant known as Delta, is still circulating in India. Kappa variant, which is related to more dangerous coronavirus variant known as Delta, is still circulating in India.](https://swarajya.gumlet.io/swarajya/2021-05/0a839fe4-f3f1-4df5-a3a3-e300cfe8e389/Coronavirus_representative_image.png)
Kappa variant, which is related to more dangerous coronavirus variant known as Delta, is still circulating in India.
![Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio](https://journals.asm.org/cms/10.1128/mbio.00099-22/asset/c355a0b9-458b-4bbe-880e-f48e46e35db6/assets/images/medium/mbio.00099-22-f005.gif)
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio
![Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing | Experimental & Molecular Medicine Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing | Experimental & Molecular Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs12276-021-00691-y/MediaObjects/12276_2021_691_Fig1_HTML.png)
Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing | Experimental & Molecular Medicine
![Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio](https://journals.asm.org/cms/10.1128/mbio.00099-22/asset/436f63da-2f4b-48a5-8830-b18e77712537/assets/images/medium/mbio.00099-22-f003.gif)
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion | mBio
![Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies | Cell Discovery Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies | Cell Discovery](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41421-021-00347-1/MediaObjects/41421_2021_347_Fig1_HTML.png)
Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies | Cell Discovery
![Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission - ScienceDirect Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1931312822000427-fx1.jpg)
Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission - ScienceDirect
![Frontiers | Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations? Frontiers | Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?](https://www.frontiersin.org/files/Articles/763169/fmicb-13-763169-HTML/image_m/fmicb-13-763169-g001.jpg)
Frontiers | Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?
![DNA Explainer: Kappa variant of COVID-19 - Know all about its mutations, symptoms and vaccine efficacy DNA Explainer: Kappa variant of COVID-19 - Know all about its mutations, symptoms and vaccine efficacy](https://cdn.dnaindia.com/sites/default/files/2021/07/09/984384-kappa-variant-covid-19.jpg?im=FitAndFill=(1200,900))